Vital Therapies (VTL) Earns Buy Rating from William Blair

William Blair reiterated their buy rating on shares of Vital Therapies (NASDAQ:VTL) in a research report sent to investors on Sunday morning.

Several other research analysts have also recently weighed in on the company. BTIG Research reaffirmed a hold rating on shares of Vital Therapies in a research note on Thursday, August 9th. BidaskClub raised Vital Therapies from a buy rating to a strong-buy rating in a research note on Thursday, July 12th. ValuEngine raised Vital Therapies from a hold rating to a buy rating in a research note on Friday, June 29th. Finally, Zacks Investment Research raised Vital Therapies from a sell rating to a hold rating in a research note on Saturday, May 12th. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of Buy.

Shares of VTL stock opened at $8.85 on Friday. Vital Therapies has a fifty-two week low of $2.65 and a fifty-two week high of $9.75. The stock has a market cap of $398.27 million, a P/E ratio of -6.76 and a beta of 4.21.



Vital Therapies (NASDAQ:VTL) last announced its earnings results on Tuesday, August 7th. The company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.03. equities analysts forecast that Vital Therapies will post -1.13 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the stock. Redmile Group LLC acquired a new position in shares of Vital Therapies in the 2nd quarter valued at $7,502,000. BlackRock Inc. boosted its position in shares of Vital Therapies by 134.8% in the 2nd quarter. BlackRock Inc. now owns 2,242,025 shares of the company’s stock valued at $15,356,000 after purchasing an additional 1,287,310 shares during the period. Schwab Charles Investment Management Inc. acquired a new position in shares of Vital Therapies in the 2nd quarter valued at $388,000. Quantitative Systematic Strategies LLC acquired a new position in shares of Vital Therapies in the 2nd quarter valued at $139,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Vital Therapies by 163.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 87,942 shares of the company’s stock valued at $602,000 after purchasing an additional 54,611 shares during the period. Institutional investors and hedge funds own 28.35% of the company’s stock.

About Vital Therapies

Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.

Featured Story: Stock Symbols Definition, Examples, Lookup

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply